With early detection of prostate cancer recognised as a critical part in reducing the disease’s mortality rate, PanGIA Biotech has shared results from a study validating its artificial intelligence (AI)-based liquid biopsy in vitro diagnostic (IVD) for detecting early prostate cancer from urine samples.
The US company’s detection methodology involves analysing urinary biosignatures using AI and machine learning models, which the company asserts may prove beneficial over invasive biopsies or blood-based tests that may miss early-stage cases while also eliminating the need for sequencing.
Go deeper with GlobalData
PanGIA’s prospective study involved 197 biopsy-confirmed prostate cancer patients and 84 healthy controls, with the test demonstrating strong performance in detecting intermediate- and low-grade cancers, and high recall (>0.89) across Gleason scores 6 through 10. The AI/ML classification model was also found to be effective as measured by F1 score.
The study’s findings were presented at the American Society of Clinical Oncology (ASCO) 2025 meeting, taking place in Chicago, Illinois between 30 May and 3 June.
“This study confirms what we’ve believed from the start: there’s power in non-invasive, data-driven diagnostics,” PanGIA CEO Holly Magliochetti.
“Our platform helps clinicians detect prostate cancer when intervention is most effective – without costly or invasive procedures.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataPast research indicates that with early detection, the five-year survival rate for prostate cancer is over 99%.
According to GlobalData’s Pipeline Products database, there are 142 prostate cancer IVDs at active stages of development globally. Growing at a CAGR of 3.5%, the overall global IVD market is forecast to reach a valuation of around $45.9m by 2024, up from $32.4m in 2024, as per GlobalData analysis.
In other prostate cancer news from ASCO 2025, researchers from the UK’s Institute of Cancer Research (ICR) and University College London (UCL) demonstrated that an AI-based test developed by US-based Artera can help identify which men with non-metastatic high-risk prostate cancer are most likely to benefit from being administered abiraterone.
A recent large report by Philips on the passage of AI adoption and innovation in healthcare reflected that while clinicians are chiefly on board with the AI and recognise its value in healthcare settings, 46% of respondents stated that slow adoption of AI was contributing towards missed opportunities for early diagnosis and intervention.
